Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
montanide isa51 (1 trial)
ny-eso-1 and melan-a/mart-1 peptides (1 trial)
vemurafenib (zelboraf) (1 trial)
interferon alpha-2b (Intron-A) (1 trial)
pembrolizumab (keytruda) (1 trial)
selumetinib (Koselugo) (1 trial)
Melanoma (Phase 2)
Recurrence (Phase 2)
Uveal Neoplasms (Phase 1)
Trials (4 total)
Trial APIs (6 total)